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Background: Gout is estimated to affect 1.4% of adults in the UK. Appropriate and timely management is essential to
reduce the risk of further flares, complications, and to reduce cardiovascular disease risk. The British Society for
Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR) and the European League Against
Rheumatism (EULAR) have published guidance regarding the management of gout, thereby providing standards against
which performance can be measured. This audit was designed to assess the extent to which patients diagnosed with
gout in one primary care medical practice in North Staffordshire, UK, are managed in accordance with current best
practice guidelines, and to identify strategies for improvement where appropriate.
Methods: Audit criteria were derived from the EULAR and BSR/BHPR guidelines; standards were set arbitrarily, but with
consideration of patient comorbidity and other factors which may influence concordance. An electronic search of the
practice records was performed to identify adults with a diagnosis of gout. Medical record review with a descriptive
analysis was undertaken to assess the extent to which medical management adhered to the predefined standards.
Results: Of the total ≥18 year-old practice population (n = 8686), 305 (3%) patient records included a diagnosis of gout.
Of these, 74% (n = 226) had an electronic record of serum uric acid (SUA), and 11% (n = 34) and 53% (n = 162) a
measure of estimated glomerular filtration rate (eGFR) ever and serum glucose since diagnosis respectively. 34%
(n = 105) of patients had ever taken urate-lowering therapy with 25% (n = 77) currently prescribed this at the time of data
extraction. Dose adjustment and monitoring of treatment according to SUA was found to be inadequate. Provision of
lifestyle advice and consideration of comorbidities was also lacking.
Conclusions: The primary care management of gout in this practice was not concordant with national and international
guidance, a finding consistent with previous studies. This demonstrates that the provision of guidelines alone is not
sufficient to improve the quality of gout management and we identify possible strategies to increase guideline
adherence.
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The estimated prevalence of gout amongst the UK popu-
lation is 1.4%. The UK annual primary care consultation
prevalence among adults ≥18 years is between 4.2/1000
and 4.9/1000 [1]. Prevalence increases with age such that
7% of men aged 75-84 yr are affected [2]. Timely and
effective treatment of gout is necessary to reduce the* Correspondence: e.cottrell@keele.ac.uk
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reproduction in any medium, provided the orrisk of further flares, chronic polyarthritis and tophac-
eous disease [3].
Current guidelines by the British Society for Rheumatol-
ogy and British Health Professionals in Rheumatology
(BSR/BHPR) [3] and the European League Against
Rheumatism (EULAR) [4], relating to the management of
gout in primary care are similar and may be used by pri-
mary care health professionals in the UK. Both guidelines
encourage urate-lowering therapy (ULT) if patients have
two or more attacks of acute gout, or have other risk
factors that would make further attacks likely. In suchLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to the serum uric acid (SUA). The EULAR guidelines sug-
gest a target SUA of ≤360 μmol/l while the BSR/BHPR
guidelines advocate a lower target (SUA ≤300 μmol/l). Both
EULAR and BSR/BHPR suggest commencing allopurinol
at a dose of 100 mg/day (BSR/BPHPR 50-100 mg/day) and
increasing by 100 mg (50-100 mg) every few weeks accord-
ing to SUA and renal function [3,4]. The systemic inflam-
matory response in acute gout commonly leads to a
transient reduction in SUA [5], therefore BSR/BPHPR
guidelines suggest SUA is checked 4–6 weeks post-flare [3].
In addition to ULT, guidelines recommend that pa-
tients should be given lifestyle advice where appropriate
to modify risk factors for hyperuricaemia and gout.
Guidelines recommend: optimising weight and dietary
modifications, particularly restricting the intake of
purine-rich foods and limiting alcohol consumption
[3,4]. Intervention studies show that weight loss and re-
striction of dietary purines have modest urate-lowering
effects [6,7].
The primary care management of gout has previously
been examined. In 2000, prior to the publication of the
current BSR/BHPR and EULAR guidelines, Pal et al. [8]
undertook an audit of 74,111 patients from 12 practices
in the UK. Following the publication of the EULAR rec-
ommendations for the management of gout in 2007,
Roddy et al. used a questionnaire survey to study the
management of primary care patients in two general
practices in the UK [9]. Further information from the
USA was gathered by Wall et al. [10] who undertook a
review of medical records of patients seen with gout
between 2004–7 to compare care against guideline rec-
ommendations. Common to all previous findings is that
many patients have an inadequately controlled SUA level
and have not received or retained adequate lifestyle in-
formation [8-10].
The aim of this audit was to extend assessment of
practice beyond the scope of previous work so as to in-
clude a comprehensive assessment of the approaches to
lifestyle modification and medical management of gout
itself, and to assess the extent to which such manage-
ment is in line with current best practice guidelines. The
wider implications of this diagnosis on the patient’s over-
all risk of morbidity and mortality will also be addressed
through consideration of associated comorbidities and
cardiovascular risks.Methods
Standards, criteria and targets
Audit criteria were derived from the EULAR and BSR/
BHPR guidelines. Standards were set following consider-
ation of guideline recommendations and patient comorbid-
ities. Audit criteria and standards are outlined in Table 1.Inclusion criteria
All adult patients currently registered with the practice
who had a Read-coded diagnosis of gout in their medical
record were eligible for inclusion in the audit. Read
codes form a hierarchical system for recording morbidity
types as well as symptoms, processes of care, and admin-
istrative information, and are commonly used as the
basis of consultation recording in UK general practice.
Search strategy
This audit was undertaken at one research-ready [11],
advanced training primary care medical practice in
North Staffordshire on 19th July 2012. An electronic
record search (INPS Vision version 3) using the Read
codes “Of type C34..00 Gout” and “Of type N023.00
Gouty arthritis” was undertaken to identify patients
with a current or past diagnosis of gout. All patients
identified by the search who had related diagnoses,
for example asymptomatic hyperuricaemia or uric
acid renal stones, but no history of gout were
excluded.
The electronic records of all relevant patients were
searched to identify those who had a record of SUA
(search “Uric acid blood level”), serum glucose (search
“blood glucose”, “fasting glucose”), renal function (search
“serum electrolytes”, “urea and electrolytes”, “glomerular
filtration rate”), cardiovascular disease (CVD) risk as-
sessment (search “scoring test result”), and ever use of
ULT, diuretics and lipid lowering therapy (search drug
class “long term control of gout”, “diuretic”, “lipid
regulating drugs”).Data extraction and analysis
Medical records were reviewed by EC and VC. Data
were extracted using a standard proforma, including
information on demographic details such as gender
and date of birth, gout-related information (date of
diagnosis, prescription of ULT, SUA levels), docu-
mented CVD risk assessment and management, rec-
ommended lifestyle changes, and prescription of
diuretics and lipid lowering therapy. Date of diagnosis
was defined as the date of the first recorded entry of
a Read code pertaining to gout. In instances where
only the year was recorded, date of diagnosis was set
to 30th June of that year. ‘Current’ medication use
was defined as that which had been prescribed in the
previous two months.
Data were analysed according to the criteria and stan-
dards, defined in Table 1. Descriptive analysis was
undertaken using IBM SPSS Statistics version 20. Chi
squared test was used to compare the proportion of
people who had an eGFR recorded between those taking
ULT and those who were not.
Table 1 Standards, criteria and targets used in gout audit
Theme of care Guideline statement Criteria Standards
Assessment
of gout patients
All patients presenting with acute gout should have SUA,
renal function and glucose assessed 4-6wk after acute attack [3]
1.1 Adult patients with a diagnosis of gout have ever
had a recorded SUA
≥90%
1.2 Adult patients with a diagnosis of gout have ever
had a recorded eGFR
≥90%
1.3 Adult patients with a diagnosis of gout have had
a recorded serum glucose since diagnosis
≥90%
Management of
recurrent gout
The therapeutic goal of urate lowering therapy…is achieved by
maintaining the SUA below the saturation point for urate
(≤360 μmol/l) [4]
2.1 Adult patients currently prescribed (prescription
in the last 2 months) allopurinol have a SUA
measured in the last year
≥90%
2.2 Adult patients currently prescribed (prescription
in the last 2 months) allopurinol have an SUA≤
360 μmol/l
≥80%
Monitoring of
gout patients
Annual measurements of plasma renal function and SUA [3] 3.1 Adult patients with a diagnosis of gout have had
a SUA in the last year
≥90%
3.2 Adult patients with a diagnosis of gout have had
a eGFR measured in the last year
≥90%
Lifestyle advice All patients with gout should be given advice about diet,
alcohol restriction, weight management and fluid intake.[3,4]
4.1 Adult patients with a diagnosis of gout with
evidence of advice regarding diet recorded
≥90%
[It is recognised that such information may be provided in
written format in a patient information leaflet]
4.2 Adult patients with a diagnosis of gout with
evidence of advice regarding alcohol recorded
≥90%
4.3 Adult patients with a diagnosis of gout with
evidence of advice regarding fluid intake recorded
≥90%
4.4 Adult patients with a diagnosis of gout have a
record of BMI
≥90%
Addressing
comorbidities
Associated comorbidities and cardiovascular risk factors should be
addressed as an important part of the management of gout [4]
5.1 Adult patients with a diagnosis of gout have a
recorded CVD risk assessment score
≥90%
5.2 Adult patients with a diagnosis of gout and a
10 yr risk of CVD ≥20% are prescribed lipid lowering
therapy
≥75%
Diuretic therapy should be stopped if possible in
patients with a diagnosis of gout [3,4]
5.3 Adult patients with a diagnosis of gout currently
taking diuretics
<25%
CVD, Cardiovascular disease; eGFR, Estimated glomerular filtration rate; SUA, Serum uric acid.
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The total ≥18 yr practice population was 8686. Of these,
312 patients had an electronic diagnosis of gout, of
whom seven had renal stones only, therefore the records
of 305 (3.5%) patients with gout were analysed (see
accompanying Additional file 1). Patient characteristics
are summarised in Table 2.
Assessment of all gout patients
None of the standards relating to assessment of gout patients
were reached. Among the 305 patients with gout, 226 (74%)Table 2 Characteristics of patients with gout
Characteristic
Mean age (median, IQR) 65.5 years
(67.0 years, 54.5-77.0)
Gender male, n(%) 227 (74%)
Mean duration since first electronic
diagnosis of gout (median, IQR)
8.5 years
(6.4 years, 1.4-13.0)
Proportion currently taking ULT, n(%) 77 (25%)had ever had a recorded SUA, 34 (11%) had ever had a re-
corded eGFR and 162 (53%) had ever had a recorded serum
glucose since diagnosis (see Table 3). There was no signifi-
cant difference in the proportion of patients who had ever
had a recorded eGFR between those taking ULT (13%) and
those who were not (11%, p = 0.55).Management of recurrent gout
One-hundred and five patients (34%) had ever used
ULT. Seventy seven patients (25%) were ‘currently pre-
scribed’ ULT, of whom 76 (99%) were taking allopurinol
and one was taking probenecid. Twenty six patients had
previously been prescribed allopurinol, one had been
prescribed febuxostat and another probenecid.
Of the 76 people currently taking allopurinol, the diag-
nosis of gout was first recorded on the same day that
they were first prescribed ULT in 15 (20%). Among the
61 remaining patients currently taking allopurinol, 60
were prescribed this medication after the recorded diag-
nosis of gout (range 16 to 6527 days) and for one patient
Table 3 Attainment of standards relating to assessment of gout patients
Criterion Standard Attainment (n = 305)
1.1 Adult patients with a diagnosis of gout have ever had a recorded SUA ≥90% 226 (74%)
1.2 Adult patients with a diagnosis of gout have ever had a recorded eGFR ≥90% 34 (11%)
1.3 Adult patients with a diagnosis of gout have had a recorded serum
glucose since diagnosis
≥90% 162 (53%)
2.1 Adult patients currently prescribed (prescription in the last 2 months)
allopurinol have a SUA in the last year
≥90% 26 (34%)
2.2 Adult patients currently prescribed (prescription in the last 2 months)
allopurinol have an SUA of ≤360 μmol/l
≥80% 29 (38%)
See Figure 1 and Figure 2
3.1 Adult patients with a diagnosis of gout have a SUA in the last year ≥90% 68 (22%)
3.2 Adult patients with a diagnosis of gout have had an eGFR in the last year ≥90% 27 (9%)
4.1 Adult patients with a diagnosis of gout with evidence of advice
regarding diet recorded
>50% Diet discussed 43 (14%)
4.2 Adult patients with a diagnosis of gout with evidence of advice
regarding alcohol recorded
>50% Alcohol intake discussed 18 (6%)
Alcohol type discussed 9 (3%)
Advised about alcohol intake 17 (6%)
4.3 Adult patients with a diagnosis of gout with evidence of advice
regarding fluid intake recorded
>50% Maintain fluid intake 2 L/day 42 (14%)
4.4 Adult patients with a diagnosis of gout have a record of BMI ≥90% BMI documented 304 (100%)
– – ‘Lifestyle advice’ documented 7 (2%)
– – PIL given 11 (4%)
5.1 Adult patients with a diagnosis of gout have a recorded CVD risk assessment score ≥90% 305 105 (34%)
5.2 Adult patients with a diagnosis of gout and a 10 yr risk of
CVD ≥20% are prescribed lipid lowering therapy
≥75% 56 30 (54%)
5.3 Adult patients with a diagnosis of gout currently taking diuretics <25% 73 (24%)
BMI, Body mass index; PIL, Patient information leaflet.
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purinol prescription.
Starting doses of allopurinol were 100 mg (62%),
200 mg (6%) and 300 mg (32%). Dose adjustment had
occurred between none and five times since treatment
initiation. Most patients (n = 58) remained on the start-
ing dose and, of these patients, 19 (33%) had an SUA in
range. Six patients (8%) currently taking allopurinol had
no SUA measurements recorded.
Only three patients were taking daily doses of allopur-
inol above 300 mg. The maximum dose taken by any
patient was 600 mg. Control of SUA according to allo-
purinol dose is demonstrated in Figures 1 and 2.
Amongst previous users of allopurinol (n = 26), 300 mg
was the most common daily dose (n = 11).Monitoring patients with gout
Of the 305 patients with gout, 68 (22%) had a SUA level
and 27 (9%) had an eGFR recorded in the last year. The
proportion who had had an eGFR recorded in the last
year did not differ between those who were taking ULT
and those who were not (12% vs 8%, p = 0.31). Of the 76
patients currently taking allopurinol, 26 (34%) had aSUA level recorded in the last year and 29 (38%) had an
SUA ≤360 μmol/l (see Table 3).Lifestyle advice
Although 304 patients with gout had a recorded BMI,
recording of provision of other lifestyle advice was less
frequent. There was evidence of discussion about diet
(n = 43; 14%), fluid intake (n = 42; 14%), alcohol intake
(n = 18; 6%) and alcohol type (n = 9; 3%). General entries
pertaining to provision of lifestyle advice were identified
by noting records that contained documentation of
provision of patient information leaflets (n = 11; 4%) and
“lifestyle advice” (n =7; 2%) (see Table 3), such entries
were not mutually exclusive.Addressing comorbidities
One hundred and five (34%) patients with gout had a re-
corded CVD risk assessment score. Of those with a re-
corded ten year score ≥20% (n = 56), 30 (54%) were
receiving prescriptions for lipid lowering therapy (see
Figure 3). Seventy-three (24%) patients with a diagnosis
of gout were currently receiving a prescription for
diuretics.
Figure 1 Number of patients with SUA in range (≤360 μmol/l) and above target among current users of allopurinol according to
current daily dose.
Figure 2 SUA values according to current allopurinol dose.
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Patients with gout
n = 305
CVD score not recorded
n = 200
CVD score recorded
n = 105
Methods used:
Framingham n = 102 
QRISK 2 or QRISK = 3
CVD score <20%
n = 49
CVD score ≥20% 
n = 56 
Lipid lowering therapy prescribed
n = 30
Lipid lowering therapy not prescribed
n = 26
Figure 3 Management of CVD risk factors.
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Despite being the most prevalent form of inflammatory
arthritis, gout is often poorly diagnosed and subopti-
mally managed [4]. Current research estimates that 1-2%
of the UK adult population is affected by gout [9]. The
prevalence of gout in the audited practice (≥18 years)
was 3.5%. The results presented in this paper are import-
ant as they add to successive surveys which have shown
persistent suboptimal management of gout in primary
care. This audit is novel as it refers to both BSR/BHPR
and EULAR guidelines and is the most comprehensive
to date, covering a wider range of aspects of gout man-
agement than existing audits, namely: CVD risk factor
screening, non-pharmacological management, use of
ULT and ‘treating-to-target’. New ways to encourage
management and improve recording of care in line with
best evidence is therefore needed and should be sought
with some urgency.Assessment of all gout patients
The results demonstrated that 74% of patients with gout
had a record of SUA. Although not a pre-requisite for
diagnosis, a raised SUA supports a diagnosis of gout and
measurement is essential if ULT is to be initiated and
adequately titrated. Further, although gout with nor-
mouricaemia is well-recognised [12], persistently low
SUA may necessitate reconsideration of the diagnosis.
Gout is associated with a number of comorbidities,
the management of which may affect not only the de-
velopment of gout but also the choice of therapeutic
agent. Renal impairment and diabetes are notable
thus current guidance recommends that patients have
a record of both renal function and serum glucose
after diagnosis [3]. Only 11% of patients with gout had an
electronic record of eGFR and 53% a record of serum
glucose. More frequent screening was found in an audit of
twelve practices in 2000, which revealed that 66% of
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treatment [8].
Of the 76 patients taking allopurinol, 26 patients (34%)
had an SUA measurement recorded in the last year. Six
patients (8%) currently taking allopurinol had no SUA
measurements recorded, which is remarkable consider-
ing titration of allopurinol should occur according to
SUA level.
Management of recurrent gout
Allopurinol has been the mainstay of recurrent gout
prevention for decades. The aim of such therapy is to re-
duce the SUA below the saturation point for monoso-
dium urate thereby preventing crystal formation and
deposition within the joints [4]. A target for a SUA
of ≤360 μmol/l is set for patients on ULT. Roddy et al.
found that persistent hyperuricaemia and recurrent
acute attacks are still seen in patients taking allopurinol
and suggest that doses >300 mg are often required [9].
Of the 305 patients identified as having gout, 105
(34%) were found to have ever used ULT. Of those cur-
rently taking allopurinol, 20% were prescribed ULT on
the same day as the diagnosis was first formally coded. It
is not clear from the medical records whether the date
of diagnosis pertains to first attack or whether the pa-
tient was given additional, non-documented instructions
as to how and when to take the medication prescribed.
Historically, immediate prescriptions of allopurinol dur-
ing an acute attack have been actively discouraged for
fear of precipitating further acute flares. Although, re-
cent evidence has started to suggest this approach may
be unnecessary [13], advice about initiation should be
documented.
Potentially correctable persistent hyperuricaemia in-
creases the risk of recurrent gout flares and there is also
an association with increased cardiovascular morbidity
[14,15]. Current guidance regarding the initiation of allo-
purinol recommends a starting dose of 100 mg daily,
with incremental increase of 100 mg every few weeks
until the target level for SUA is achieved [3,4]. Only 62%
patients were started on allopurinol at a dose recom-
mended in the guidelines. Of those 102 patients ever
prescribed allopurinol, the majority (57%) remained on
the starting dose for the duration of therapy. When SUA
among patients prescribed allopurinol was examined,
only 34% of patients on ULT had a SUA recorded in the
last year and only 29 (38%) patients had their latest SUA
≤360 μmol/l. These findings suggest that active titration
of allopurinol according to SUA measurement in line
with expert consensus [3] is not occurring in most pa-
tients, something that is not unique to this practice [16].
Wall et al. [10] also found that monitoring and dose ti-
tration against SUA was suboptimal, only 29% of pa-
tients in a suburban clinic having evidence of annualSUA measurement (average SUA ≈ 430 μmol/l among
urban clinic and ≈ 410 μmol/l among patients in the
suburban clinic). Roddy et al. [9] also found that only
9% of patients were taking allopurinol doses above
300 mg daily but 23% of patients taking allopurinol had
SUA >360 μmol/l.
Lifestyle advice
Provision of lifestyle advice appeared infrequent, echoing
the findings of Pal et al. and Roddy et al. [8,9], although
it is possible that this reflects poor documentation, ra-
ther than inadequate provision. However, this finding is
not unique to gout with dietary advice documented in
the primary care record of 43% patients at high risk of
CVD and weight loss in 66% [17]. Historically there was
no research data demonstrating a positive effect of edu-
cation on gout and its treatment [4], however there was
a general agreement that education does improve out-
come. A recent study of patients referred to rheumatol-
ogy outpatients has demonstrated that provision of
information and education about the disease, its risk fac-
tors, clinical consequences and management strategies
by a rheumatologist with specialist nurse follow up (tele-
phone or in person) could result in 92% of patients
achieving a SUA ≤360 μmol/l, with an average allopur-
inol dose of 400 mg daily and a reduction in pain at
twelve months [18]. There remains a need to identify if
such improvements can be gained from a primary-care
based education approach and in a more general pri-
mary care population [17].
Addressing comorbidities
Gout is associated with a number of comorbidities in-
cluding metabolic syndrome, CVD, hypertension, and
diabetes [2,19].
Of the 305 patients with gout, 73 patients (24%) were
identified as taking at least one diuretic. This is similar
to previous published findings which have identified the
proportion of patients with gout taking diuretics ranging
from 15-34% [2,8-10]. Although it is recognised that re-
cent research evidence has not consistently demon-
strated a trend towards a higher risk of acute gout in
those patients receiving diuretic therapy [20], if diuretics
are thought to be a precipitating or perpetuating factor
through their effects on SUA, novel approaches to redu-
cing such prescriptions may be required [4].
This audit looked for evidence of assessment of CVD
risk. Indeed, both EULAR and BSR advocate CVD
screening and subsequent treatment of risk factors in
patients with gout [3,4]. Roddy et al. found that 31% of
patients presenting with acute gout had undergone
comorbidity screening within the 12 months prior to
index consultation [21]. Similar suboptimal adherence to
current recommendations was observed in the current
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was found in only 34% of patients, of which 53% had a
10 yr CVD risk assessment score of ≥20%. Although
those at higher risk may have a differentially high level
of recording due to targeted intervention by clinicians,
rigorous CVD risk assessment among the entire gout
population may prove fruitful in detecting patients who
stand to benefit from primary prevention methods.
Limitations
Data collection relied on the presence of a Read-coded
diagnosis of gout in the medical record. Although the
high prevalence in this audit suggests that omission of
substantial numbers of patients with gout is unlikely
(e.g. those who have been given a joint symptom code),
the methods do not exclude patients with an erroneously
recorded diagnosis. Primary care consultation records
have been widely used in gout research. In one such
study, undertaken using consultation data, scrutiny of
consultation free text recorded by GPs confirmed fea-
tures of inflammation and distribution of affected joints
generally consistent with a diagnosis of gout [21].
The duration of disease in people with gout has not
been accurately detected by this audit. Analysis of the
free-text associated with the coded diagnosis indicated
that at least 15% probably had prior uncoded episodes.
Pal et al. searched for people with diagnosis of gout and
those on treatment for gout [8]. Such a method might
have a greater sensitivity for detection of gout cases.
We found that 20% of patients currently taking allo-
purinol were recorded as being diagnosed with gout on
the same day that they were first prescribed this ULT,
demonstrating that either the diagnosis was made or
coded retrospectively, or that management guidelines
are not being followed.
As data was obtained from electronic records alone, it
is impossible to estimate the frequencies with which epi-
sodes occurred for which patients did not consult. Thus
adherence to guidelines regarding ULT initiation could
not reliably be determined nor could the appropriateness
of the timings of SUA measurements.
Current’ prescriptions were defined as those in which
a prescription had been created in the two months pre-
ceding the audit search date. This method may over- or
underestimate actual medication use. A more accurate
picture may be obtained through conversion to defined
daily doses.
This paper represents work from only one location,
thus patient numbers are relatively small and will have
limited direct generalisability. However, the findings
from this audit do not differ greatly from published re-
sults of other audits and studies, indicating that the
management of gout has not improved over the past
decade. Data regarding ethnicity was not collected forthis audit. The Office for National Statistics 2011 data
suggests that the source population has a low represen-
tation of ethnic minority groups compared to the na-
tional picture [22].
This audit did not examine co-prescription of prophy-
lactic medication at initiation of ULT to prevent acute
flares. Although the importance of this is recognised,
non-steroidal anti-inflammatory drugs are available over
the counter thus actual patient use cannot be accurately
quantified and record review may lead to under-
estimation.Recommendations
A survey of UK General Practitioners in 2002 revealed
that an overwhelming majority (86%) claimed to be
confident in both the diagnosis and the management of
gout [23]. However, the results of this audit are amongst
many that have found that management of gout to be sub-
optimal, demonstrating poor concordance with current
recommendations and guidelines [4,8,10,15,24,25] leading
to many patients having SUA levels above target. Since
this audit was undertaken, the American College of
Rheumatology (ACR) have also published guidelines on
the management of gout [26,27]. These newest guidelines
continue to recommend patient education on diet, lifestyle
and management of comorbidities as core features of gout
management, describe allopurinol (or febuxostat) as first-
line for lowering SUA and support previous allopurinol
initiation and titration strategies [26]. The ACR guidelines
also include additional recommendations such as more
formalised consideration of causes of hyperuricemia, spe-
cific subgroup screening and combination or single novel
pharmacological strategies. If we are to improve our
management of gout through consideration of recent
evidence-based recommendations, it is imperative that we
first address deficiencies in the long-standing basics of
management. Based on the findings of this audit and other
work published for over a decade, several recommenda-
tions are made to facilitate improvement in the quality of
care of patients with gout thereby reducing morbidity and
associated CVD mortality and ultimately reduce the bur-
den of disease.Education of the general public
Through raising public awareness of gout and the poten-
tial implications and links to other aspects of ill-health,
it may be possible to modify health-seeking behaviour,
thus encouraging presentation to primary care. Patient
education may improve compliance with therapy, life-
style modification and motivation to change, especially
since the popular stereotypes of patients with gout are
outdated and inaccurate.
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and management of gout
Before GPs will adhere to recommendations in guide-
lines, they need to first be aware of them [28]. Strategies
to increase awareness must include improved, accessible
dissemination and promotion of the key recommenda-
tions from current guidelines. The use of routine quality
indicators of care [29] may also be beneficial to prompt
GPs to consider best evidence-based care. Ideally pa-
tients should be involved in the development of quality
indicators to ensure they address priority areas, and take
into account the preferences of, the target population
[30]. Education regarding the importance of gout as a
risk factor for cardiovascular disease and the importance
of screening for modifiable risk factors may provide fur-
ther impetus to improve care. Locally the authors acted
on the audit findings in the practice by outlining the
guideline recommendations, highlighting current defi-
ciencies in records of care and arranging for a local ex-
pert to give a talk to the practice team. More widely,
presentation of audit findings at academic and clinical
meetings will raise awareness and prompt other profes-
sionals to reflect on their own practice. However, there
remains a need to find effective ways of nationally rais-
ing awareness of relevant recommendations across pri-
mary care.Widen guideline development groups to involve patients
and primary care professionals
Once professionals are aware of guidelines, they must
agree with the contents before they will adopt them [28].
Involving primary healthcare professionals in guideline
development for the management of gout will ensure
that recommendations are relevant and deliverable
within primary care. Further, through adequate represen-
tation of patients in guideline development groups,
guidelines that address patient’s priorities, taking into ac-
count their lived experiences of the condition, will also
be developed. Although the Arthritis and Musculoskel-
etal Alliance (ARMA) standards for the management of
gout [31] included primary care representatives, neither
the EULAR nor BSR/BHPR guidelines, which provided
the standards for this audit, included a GP, nor did they
clearly involve a patient, in their development groups.Consider financially incentivising gout care or
demonstrating pre-existing related targets
Gout is not currently part of the UK payment-for-
performance scheme, the Quality and Outcomes Frame-
work (QOF). Maisey et al. have previously found that
whilst substantial improvement in the quality of care of
conditions included in QOF was observed, the same was
not so for other non-incentivised conditions [32]. It ispossible that incentivising care may increase both aware-
ness and adoption of best evidence guidelines.
Educate healthcare professionals and administrative staff
about the importance of specific and accurate coding
It is known that diagnostic coding of acute conditions is
not always accurate [33]. The accuracy and consistency
with which coding is performed could be improved by
educating healthcare professionals and administrative
staff about the importance of and/or encouraging use of
specific and accurate coding to promote continuity of
care, optimise management through a systematic annual
recall system and allow for accurate routine audit and
epidemiological research.
Reorganising gout management in primary care
The final step in providing best evidence care from
guidelines is to adhere to the guidelines [28]. Adherence
may be encouraged through the use of prompts trig-
gered by disease-specific Read codes during individual
consultations. Integration of clinical templates, to ensure
that appropriate advice, drug titration, review of existing
medications and investigations are undertaken may ad-
dress some deficiencies. Such a template-based system
could be triggered by prescription or medication review
of allopurinol, and could facilitate practice nurse follow-
up and dose titration once patients have been counselled
about and commenced on allopurinol by their GP.
Future research
To have a major driver for change in the management of
gout, further work to understand the link between gout
and CVD is needed. In particular, the benefits of con-
trolling hyperuricaemia and any reduction in concomi-
tant CVD risk should be carefully assessed. This novel
approach to the risks associated with persistently ele-
vated SUA would help both clinicians and patients to
prioritise the management of gout in the context of indi-
vidual and population morbidities. Further, qualitative
investigation into the attitudes and beliefs of GPs and
patients regarding the management of gout as well as
awareness and experiences of implementing current
guidelines would provide additional information that
may highlight barriers to improving evidence based
practice.
Additional file
Additional file 1: Identification of patient sample and measurement
of serum uric acid among patients with gout.
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